Pictet Asset Management
IOVA icon

Pictet Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Pictet Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151K Buy
43,048
+15,926
+59% +$50.9K ﹤0.01% 1986
2025
Q4 		$74K Hold
27,122
– – ﹤0.01% 2050
2025
Q3 		$58.9K Hold
27,122
– – ﹤0.01% 2019
2025
Q2 		$46.6K Sell
27,122
-893,339
-97% -$2.22M ﹤0.01% 1989
2025
Q1 		$3.27M Buy
920,461
+89,402
+11% +$461K ﹤0.01% 849
2024
Q4 		$6.15M Sell
831,059
-71,209
-8% -$660K 0.01% 773
2024
Q3 		$8.66M Sell
902,268
-17,809
-2% -$169K 0.01% 691
2024
Q2 		$7.38M Sell
920,077
-2,330,477
-72% -$25M 0.01% 704
2024
Q1 		$47.5M Sell
3,250,554
-2,012,755
-38% -$23.4M 0.05% 319
2023
Q4 		$42.8M Sell
5,263,309
-1,650,375
-24% -$8.64M 0.05% 339
2023
Q3 		$31.5M Buy
+6,913,684
New +$45.1M 0.04% 359

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Pictet Asset Management's IOVA Position: Q1 2026 in Review

Pictet Asset Management increased its Iovance Biotherapeutics (IOVA) stake by 59% in Q1 2026, buying an estimated $50.9K and bringing the position to 43,048 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #1986.

Pictet Asset Management first reported a position in IOVA in Q3 2023 and has held it in 11 quarters since. The position peaked at $47.5M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Pictet Asset Management held 43,048 shares of Iovance Biotherapeutics worth $151K as of Q1 2026.
  • Pictet Asset Management bought 15,926 Iovance Biotherapeutics shares in Q1 2026, an estimated $50.9K.
  • Iovance Biotherapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1986 holding.
  • Pictet Asset Management first reported a position in Iovance Biotherapeutics in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Iovance Biotherapeutics position peaked at $47.5M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.